Contribute Try STAT+ Today

A coalition of consumer groups and unions have asked the Federal Trade Commission to block AbbVie (ABBV) from proceeding with its proposed $63 billion acquisition of Allergan (AGN) in order “to prevent further harm to consumers.”

In arguing their case, the groups contend pharmaceutical industry has become increasingly concentrated, which has often caused higher prices and reduced choices. Moreover, they also maintained both companies have “engaged in a wide variety of anticompetitive conduct to stifle competition including restrictive contracting practices and intellectual property abuse.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.